Hershey Company (The) vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Hershey PA chocolate and snacks (NYSE: HSY) ~$10.2B FY2024 revenue; Reese's #1 US candy brand, cocoa inflation $2.5K→$12K/MT crisis, SkinnyPop salty snacks, competing with Mars and Ferrero.
About
The Hershey Company is a Hershey, Pennsylvania-based confectionery and snacks company — publicly traded on the New York Stock Exchange (NYSE: HSY) as an S&P 500 Consumer Staples component — manufacturing and selling chocolate, candy, mints, gum, and salty snacks through iconic brands including Hershey's (chocolate bars, Kisses), Reese's (peanut butter cups — America's #1 candy brand by revenue), Kit Kat (licensed from Nestlé for the US market), York Peppermint Patties, Jolly Rancher, Ice Breakers, Skinny Pop, Dot's Pretzels, and Pirate's Booty through approximately 18,000 employees in 80+ countries. In fiscal year 2024, Hershey reported net sales of approximately $10.2 billion, with earnings per share significantly compressed by unprecedented cocoa commodity inflation: West African cocoa prices (Ghana and Ivory Coast provide 70%+ of global cocoa supply) surged from $2,500/metric ton in 2022 to over $12,000/metric ton in early 2024 — the highest prices in 50+ years — driven by El Niño-related drought and crop disease (swollen shoot disease) reducing cocoa harvests, creating a chocolate manufacturer cost crisis that Hershey absorbed through price increases and hedging while managing volume declines as consumers resisted higher candy prices. CEO Michele Buck has guided Hershey through the cocoa inflation crisis by implementing 10-15% retail price increases in 2023-2024, reformulating some lower-margin products to reduce cocoa content, and hedging cocoa commodity exposure on a rolling 12-18 month forward basis to smooth out extreme spot price volatility.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.